Literature DB >> 816975

Pathogenesis of cutaneous lesions in acute meningococcemia in humans: light, immunofluorescent, and electron microscopic studies of skin biopsy specimens.

M N Sotto, B Langer, S Hoshino-Shimizu, T de Brito.   

Abstract

Biopsy specimens of the skin were taken from 10 patients with acute meningococcemia who exhibited mainly maculopurpuric lesions. The specimens were studied by light, electron, and immunofluorescent microscopy in an attempt to obtain information on the pathogenesis of vascular injury. Light microscopy disclosed a large number of Neisseria meningitidis organisms, both in the endothelial cells and being phagocytized by neutrophils. Vascular injury was characterized (by means of both light and electron microscopy) by endothelial necrosis, thrombosis, and necrosis of other elements of the vascular wall, such as muscle cells and pericytes. Immunoglobulins and complement were also found in the vascular wall in most cases. Hypercoagulability was demonstrated in some patients. These findings suggest that the cutaneous lesions of meningococcemia fulfill most of the gross and histologic criteria of the local Shwartzman reaction, but that immunological factors probably contribute to pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 816975     DOI: 10.1093/infdis/133.5.506

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Analysis of pathogen-host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo.

Authors:  O B Harrison; B D Robertson; S N Faust; M A Jepson; R D Goldin; M Levin; R S Heyderman
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

2.  Platelet and soluble CD40L in meningococcal sepsis.

Authors:  David P Inwald; Saul N Faust; Paula Lister; Mark J Peters; Michael Levin; Robert Heyderman; Nigel J Klein
Journal:  Intensive Care Med       Date:  2006-06-30       Impact factor: 17.440

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Meningococcal septicaemia presenting as drug hypersensitivity.

Authors:  A K Mier; C W Havard
Journal:  J R Soc Med       Date:  1986-07       Impact factor: 5.344

5.  Meningococcal septicaemia and meningitis: a rising tide.

Authors:  G V Raman
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-23

6.  Rare complications in a case of generalized meningococcal disease: immunologic reaction versus bacterial metastasis.

Authors:  U Stephani; H Bleckmann
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

7.  Invasive meningococcal disease presenting as Henoch-Schonlein purpura.

Authors:  M N Tsolia; A Fretzayas; H Georgouli; G Tzanakaki; S Fessatou; G Liapi-Adamidou; A Constantopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

8.  High-level endothelial E-selectin (CD62E) cell adhesion molecule expression by a lipopolysaccharide-deficient strain of Neisseria meningitidis despite poor activation of NF-kappaB transcription factor.

Authors:  G L J Dixon; R S Heyderman; P van der Ley; N J Klein
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

9.  Endothelial adhesion molecule expression and its inhibition by recombinant bactericidal/permeability-increasing protein are influenced by the capsulation and lipooligosaccharide structure of Neisseria meningitidis.

Authors:  G L Dixon; R S Heyderman; K Kotovicz; D L Jack; S R Andersen; U Vogel; M Frosch; N Klein
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

10.  Adhesion of Neisseria meningitidis to dermal vessels leads to local vascular damage and purpura in a humanized mouse model.

Authors:  Keira Melican; Paula Michea Veloso; Tiffany Martin; Patrick Bruneval; Guillaume Duménil
Journal:  PLoS Pathog       Date:  2013-01-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.